Pharmasyntez-Nord has successfully completed the certification process for compliance with the international Good Manufacturing Practice (GMP) standards in Brazil. This milestone is historic for the Russian pharmaceutical industry, as Pharmasyntez-Nord has become the first Russian company to obtain certification for manufacture of a Finished Pharma Product (FPP) in this key South American region. Pharmasyntez-Nord facility has obtained a Good Manufacturing Practice compliance certificate from ANVISA, the Brazilian regulatory authority.

GMP certification is a crucial aspect of ensuring pharmaceutical quality and safety. This certification ensures that the manufacturing processes meet the rigorous international standards, fostering trust among consumers and healthcare professionals.

Nikita Punia, Executive Director of Pharmasyntez Group, outlined the plans for expanding pharmaceutical supply partnerships in LATAM:

"Pharmasyntez-Nord intends to initiate the registration process for its products on the Brazilian market in Q1 2025. This represents a strategic move to strengthen our presence in Latin America while demonstrating our dedication to delivering high-quality finished products.